Related Experiment Video

Updated: May 17, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness

Simona Pavan1, Martina Olivero, Davide Corà

  • 1Department of Oncological Sciences, University of Torino School of Medicine, Turin, Italy.

European Journal of Cancer (Oxford, England : 1990)
|October 20, 2012
PubMed
Abstract

Insights

Interferon Regulatory Factor-1 (IRF-1) is upregulated by cisplatin in ovarian cancer cells. While IRF-1 may limit treatment response by inhibiting proliferation, its silencing sensitizes cells to cisplatin-induced apoptosis.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Interferon Regulatory Factors (IRFs) are key transcription factors in immune responses and oncogenesis, often acting as tumor suppressors.
  • IRF expression and activation are triggered by cytokines and DNA damage.
  • This study investigates the role of IRF-1 in ovarian cancer cell response to cisplatin (CDDP).

Purpose of the Study:

  • To elucidate the function of IRF-1 in ovarian cancer cells treated with cisplatin.
  • To determine how IRF-1 influences cellular responses like proliferation, apoptosis, and cell cycle progression.

Main Methods:

  • Transcriptional profiling of ovarian cancer cells using expression microarrays after CDDP treatment and IRF-1 silencing.
  • Functional assays including cell cycle analysis, colony formation, and apoptosis assessment following IRF-1 manipulation (silencing and overexpression).

Main Results:

  • CDDP treatment increased IRF-1 expression and nuclear translocation in ovarian cancer cells, altering target gene expression.
  • IRF-1 overexpression suppressed the transformed phenotype and induced G1 arrest and p21 expression.
  • IRF-1 silencing sensitized cells to CDDP-induced apoptosis and reduced p21 induction.

Conclusions:

  • IRF-1 is upregulated by CDDP in ovarian cancer cells and may limit therapeutic efficacy by inhibiting proliferation.
  • IRF-1 induction could potentially antagonize the effectiveness of combination therapies involving platinum drugs and cytokines.

More Related Videos

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.